Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCFLRH)

• Drug Name: Cibinetide Drug Info
• Synonyms: UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Phase 2	[1]
Neuropathic pain	8E43.0	Phase 2	[2]
Sarcoidosis	4B20.5	Phase 2	[3]
Diabetic macular edema	9B71.02	Phase 1	[4]
Peripheral neuropathy	8C0Z	Phase 1	[5]

• Cross-matching ID:
  PubChem CID: 91810664
  CAS Number: CAS 1208243-50-8
  TTD Drug ID: DMCFLRH

Molecule-Related Drug Atlas

Drug(s) Targeting Erythropoietin Receptor (EPOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Darbepoetin alfa	DMMJTYW	Anemia	3A00-3A9Z	Approved	[6]
Epoetin alfa	DMKWB73	Anemia	3A00-3A9Z	Approved	[7]
Methoxy polyethylene glycol-epoetin beta	DMK1LZD	Kidney transplant rejection	NE84	Approved	[8]
RHuEPO	DMALNG0	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
ErepoXen	DM9YI2C	Anemia	3A00-3A9Z	Phase 3	[10]
Epoetin zeta	DM9QPOU	Anemia	3A00-3A9Z	Phase 3	[11]
Hematide	DMUE843	Anemia	3A00-3A9Z	Phase 3	[12]
GlycoPEGylated erythropoietin	DM5JKCL	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[13]
Albupoietin	DMXK4CI	Anemia	3A00-3A9Z	Terminated	[14]
BBT-009	DM2YTXL	Anemia	3A00-3A9Z	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erythropoietin Receptor (EPOR)	TTAUX24	EPOR_HUMAN	Agonist	[5]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035038)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
• [7] 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
• [8] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
• [10] Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
• [11] Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
• [12] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [13] Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704.
• [14] Clinical pipeline report, company report or official report of cogenesys.